CommercialCoverageLow impact
08.02.44, Revakinagene taroretcel-lwey (Encelto®)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Dec 29, 2025
We identified it
Jun 19, 2026
Summary
A new policy for Revakinagene taroretcel-lwey (Encelto®) has been established under Commercial plans. This appears to be coverage guidance for a new gene therapy treatment that will become effective at the end of 2025.
Action Required
By December 29, 2025: Billing team should review the full policy details at the provided URL to understand coverage criteria, prior authorization requirements, and billing procedures for Revakinagene taroretcel-lwey (Encelto®). Update billing system with any required codes and authorization processes once full policy details are available.